ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.691,32
0,05%
S&P 500
5.267,84
-0,74%
Dow Jones
39.065,26
-1,53%
Euro vs US Dollar
1,08095
-0,03%
Bitcoin
67.667,04
-0,38%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Inotek Pharmaceuticals Corp. (delisted) (ITEK)

  7. Inotek Pharmaceuticals Corp. (delisted) (ITEK) News

ITEK

INOTEK PHARMACEUTICALS CORP (ITEK)

Inotek Pharmaceuticals Corp. (delisted)
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ITEK
DatumZeitQuelleÜberschriftSymbolFirma
14/02/201823h51Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
14/02/201822h48Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
13/02/201822h52Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
09/02/201822h35Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
08/02/201818h59Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
05/02/201821h25Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
31/01/201820h31Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
26/01/201820h42Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
25/01/201823h14Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
25/01/201822h16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
23/01/201823h43Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
19/01/201823h03Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
19/01/201819h52Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
16/01/201822h10Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
16/01/201822h09Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
11/01/201822h32Edgar (US Regulatory)Amended Securities Registration (section 12(b)) (8-a12b/a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
05/01/201822h07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
22/12/201722h54Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
22/12/201722h52Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
04/12/201722h13Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (definitive) (defm14a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
20/11/201723h02Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prer14a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
08/11/201714h03Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
26/10/201723h23Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
12/10/201723h31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
12/10/201723h28Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
12/10/201723h20Business WireInotek Pharmaceuticals Announces Filing of Preliminary Proxy Statement for Proposed Merger with Clinical-stage Gene Therapy C...NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
12/10/201723h08Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (preliminary) (prem14a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
06/10/201722h07Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
05/10/201716h35Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
29/09/201722h30Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
 Showing the most relevant articles for your search:NASDAQ:ITEK

Kürzlich von Ihnen besucht

BOV
CEEB3
COELBA ON
USOTC
SYSXD
Sysorex (PK)
BIT
P1ZI37
NLBNPIT1ZI37 20240621 39...
LSE
RE88
Euro.bk. 27
TG
A3LAW1
AXA Bank
EU
R422S
R422S
UNSW
CUDOSETH
CudosToken
BIT
SS5NVD
Societe Generale Effekten
NASDAQ
GRMHD
USOTC
MOYFF
Mynaric (PK)
USOTC
SAGXF
AB Sagax (PK)
USOTC
VCUFF
Vizsla Copper (QB)
COIN
SHVRUSD
Shivers
NASDAQ
GWIIW
Good Works II Acquisition
LSE
LEED
Wisdomtree Lead
LATK
SPNDETH
Spendcoin
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten